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Chapter 1 
Clinical survey of patients with dentinhypersensitivity-like toothache evoked 
by steroid therapy in Tohoku University Hospital 
 
Introduction 
Dentine hypersensitivity (DH) is a common dental pain condition 
characterized as an intense, transient pain resulting from stimulation of 
exposed dentine, typically in response to chemical, thermal, tactile or 
osmotic stimuli (West NX, 2013). In Tohoku University Hospital, some 
patients with steroid therapy complained of DH-like toothache. However, 
there is no academic report indicating that steroid therapy induces DH-like 
toothache as a side effect, although many other side effects of steroid have 
been known such as lipodystrophy, neuropsychiatric disorders, skin 
disorders, muscle cramp, proximal muscle weakness and so on (Fardet L et 
al., 2007). In fact, many patients who take steroid therapy complained of 
severe DH-like toothache on personal weblog, twitter or facebook. Some of 
them tweeted that this toothache was one of the most annoying side effects 
as well as moon face. This information prompted us to determine the 
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relationship between steroid therapy and DH-like toothache.  
In this study, we focused on the DH-like toothache that appeared after 
taking steroid and defined it as steroid derived (SD)-toothache. We first 
retrospectively surveyed using a questionnaire the patients in the 
department of Hematology and Rheumatology of Tohoku University Hospital 
in order to determine both the prevalence and features of SD-toothache. 
Second, the patients with SD-toothache were examined whether they 
suffered from typical DH toothache or not, and the details of its features 
through the clinical examination including the pain score by visual analog 
scale (VAS) in the department of Oral Diagnosis.  
 
Subjects and Methods 
Ethics statement 
The present study was approved by the Ethics Committee of Tohoku 
University Graduate School of Dentistry, and carried out at Tohoku 
University Hospital between June 2009 and July 2012.  Written informed 
consent was obtained from all participants. This clinical survey was 
conducted following the ethical principles of medical investigation involving 
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human subjects under the Helsinki Declaration of the World Medical 
Association (http://www.wma.net). 
 
Inclusion and exclusion criteria 
The subjects were comprised of 220 patients (male: n = 40; female: n 
=180), 17 to 87 years of age (mean = 49.9 years) who attended the 
department of Hematology and Rheumatology of Tohoku University Hospital. 
Their primary diseases for steroid  therapy consisted of systemic lupus 
erythematosus (SLE: n=93), rheumatoid arthritis (RA: n=70), Sjögren 
syndrome (SS: n=17), Takayasu’s arteritis (TA: n=16), mixed connective 
tissue disease (MCTD: n=9), dematomyositis (DM: n=5) and so on. After a 
questionnaire survey, participants who experienced DH-like toothache after 
taking steroid were referred to the department of Oral Diagnosis of Tohoku 
University Hospital. Patients with dental caries including wedge-shaped 
defect and with 5 or less remained vital teeth were excluded from the 
subjects of this project, after clinical examination (dental checkup) including 
the confirmation on toothache written in questionnaire. Finally, we defined 
the DH-like toothache that appeared after taking steroid as steroid derived 
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(SD)-toothache. 
 
Methods 
A cross-sectional study were performed using a questionnaire included 
the items on gender, age, the primary disease to attend the hospital, the 
treatment for the diseases [e.g., steroid therapy (1~200 mg/day) and/or 
steroid pulse therapy (500 or 1000 mg/day)], experience of SD-toothache, and 
its details (the region, the onset point, the trigger, and the degree of pain by 
using VAS). The relationship between the above factors and SD-toothache 
were statistically analyzed between patients groups with and without 
SD-toothache.  
 
Statistical Analysis 
Fisher’s exact test and chi-squared test for comparison of qualitative data 
were used. The relationship between steroid dose and the pain sensation 
evaluated by pain score was analyzed by correlation coefficient (ρ). PASW 
statistics, version 18.0 (SPSS INC. Chicago, IL 60611, USA) was applied for 
these statistical analyses. Differences were considered significant at p < 
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0.05.  
 
Results 
SD-toothache prevalence of patients taking steroid was 17.7% (39 
subjects out of 220). There were no significant differences in prevalence of 
SD-toothache between genders (p=0.7135) and among primary diseases of 
SLE (93 subjects), RA (70 subjects), or other diseases (97 subjects) (p=0.4374). 
The prevalence of SD-toothache was significantly more frequent in the 
patients treated with steroid pulse therapy (41.2%: 7 subjects out of 17) than 
in those with non-pulse therapy (15.8%: 32 subjects out of 203; p<0.05, Fig. 
1). The correlation coefficient (ρ) between steroid dose and pain score was 
0.642, indicating a positive correlation (Fig.2). Interestingly, dose reduction 
of steroid relieved SD-toothache in all cases (data not shown). 
With regard to the onset of SD-toothache, the appearance within a 
month and within 1~3 months were the most frequent except the subjects 
who answered “unknown” (Fig. 3A). The mean days of the onset of 
SD-toothache were 94.8 days. Fig. 3B shows the types of triggers for 
SD-toothache. The most of the subjects (approximately 84%) felt toothache 
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by cold water and approximately 24% of the patients felt pain even by hot 
water. The pain occurred not in one tooth but in a number of the vital teeth 
at the same time in all cases (data not shown). Most of the pain was 
characteristically continuous (37/38, 97.4%), different from the typical DH 
toothache. Fig. 3C shows the degree of SD-toothache, “tolerable” was the 
most frequent (approximately 64%), but 31% of the patients complained of 
“intolerable” symptoms. The patients who answered “hardly anxious” were 
few (Fig. 3C).  
 
Discussion 
We demonstrated in this experiment that the patients taking steroid 
therapy frequently felt SD-toothache. We found that (1) the most of the 
patients with steroid therapy suffered from SD-toothache, (2) the pain was 
not transient but continuous, and severe, (3) the pain was often triggered by 
cool water, sometimes hot one (Fig.3B ), (4) the pain occurred not in one tooth 
but in a number of the vital teeth at the same time in all cases. Thus, there 
were some differences in quality and triggers between SD-toothache and 
well-known DH toothache. 
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We further found that the steroid pulse therapy evoked SD-toothache 
more frequently than non-pulse therapy (p<0.05, Fig. 1). In addition, the 
correlation coefficient between the dose of prednisolone and pain sensation 
showed a positive correlation (Fig. 2). These results could show that 
SD-toothache appear in a dose-dependent manner in the patients treated by 
steroid therapy. Interestingly, dose reduction of steroid relieved 
SD-toothache in our all cases, possibly indicating an apparent relationship 
between steroid therapy and induced pain (SD-toothache). This is the first 
report to demonstrate the close relationship between steroid therapy and 
DH-like toothache. However, the mechanisms of the DH-like toothache 
evoked by steroid are still unknown. 
 It is well-known that adrenocorticosteroid is an agent composed of 
glucocorticoid, one of adrenal cortical hormones, and is widely applied to the 
treatment for various diseases because it strongly suppresses inflammation 
and controls immunity (Clark JH et al., 1992; Herold et al., 2006; Meldy JC., 
1974). On the mechanisms underlying the steroid-induced DH-like toothache, 
both of the peripheral (tooth pulp) and the central nerves factors should be 
considered. In the tooth, it is reported that steroid dose-dependently inhibits 
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dentin formation in prenatal rat (Wang YJ et al., 2000). But no 
morphological changes by steroid have ever been reported in the dental pulp. 
On the other hand, some studies suggested that the relationship between 
steroid and histological reactions in the brain system. Steroids can cross the 
blood brain barrier (Bannwarth et al., 1997) and the brain has the steroid 
receptors (Fuxe et al., 1985; Cintra et al., 1994). Furthermore, steroid 
administration induces degeneration and cell death of neurons as well as 
proliferation of glial cells (Haynes et al., 2001; Ramos-Remus et al., 2002; 
Tan et al., 2002). It is consequently suggested that there is a possible 
relationship between steroid and neuronal or glial reactions relating to pain 
regulation and/or modification. Further study should be needed to find out 
the mechanisms of this toothache.  
 
Conclusion 
The patients taking steroid frequently complained of SD-toothache 
(17.7%). The degree of pain was in accordance with the dose of steroid 
therapy. The features of this SD-toothache were continuous and severe pain. 
All the patients with SD-toothache complained this toothache in many vital 
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teeth at the same time by cold water (sometimes even by hot water). This is 
the first report to demonstrate the close relationship between steroid 
therapy and steroid-evoked toothache. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
Chapter 2 
Hystopathological study on the microglial activation induced by prednisolone 
in the subnucleus caudalis of the rat trigeminal sensory complex 
 
 
Introduction 
Our clinical survey demonstrated that the patients taking steroid 
were more subject to the DH-like toothache than the patients who do not. 
However, its mechanism is still unknown. We suggested possible 
mechanisms that the neuronal or glial reactions by steroid could exert an 
influence on pain regulation and/or modification in the Chapter 1. In the 
Chapter 2, we further investigated the mechanisms in the brain with steroid 
administrated rat. 
The brainstem has several sensory and motor nuclei of the cranial 
nerves. These include trigeminal sensory and motor, facial and hypoglossal 
nuclei. Injury of their peripheral nerves causes degeneration or cell death 
of sensory and motor neurons in the trigeminal ganglion (TG) and brainstem. 
Axotomy results in increase of TG neurons and cranial motoneurons which 
express c-Jun activating transcription factor 3 (ATF3), a marker for neuronal 
degeneration (Tsuzuki et al., 2001; Park et al., 2011). Expression of 
calcitonin gene-related peptide (CGRP) is also elevated in injured 
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motoneurons within the facial and hypoglossal nuclei (Streit et al., 1989; 
Grothe, 1993; Fukuoka et al., 1999). In neonatal animals, axotomy 
activates caspase-3 and apoptosis in the TG, brainstem trigeminal sensory 
complex and facial nucleus (Vanderluit et al., 2000; Sugimoto et al., 2004, 
2005). Transection of peripheral nerves also causes glial activation in 
cranial sensory and motor nuclei (Laskawi and Wolff, 1996; Lee et al., 2010; 
Ichikawa et al., 2011). In the sensory trigeminal complex, expression of p38 
mitogen-activated protein kinase (MAPK) in glial cells is increased by 
lingual nerve injury (Terayama et al., 2011). 
Glucocorticoids (GCs) are a class of steroid hormones that bind to the 
glucocorticoid receptor (GR). GR is located in lymphocytes and GCs have 
inhibitory effects on lymphocyte proliferation (Herold et al., 2006). GCs are 
widely used to treat chronic inflammatory diseases including allergies, 
asthma and autoimmune diseases. Previous immunohistochemical studies 
have demonstrated the presence of GR in the brain (Fuxe et al., 1985; Cintra 
et al., 1994). Neuronal and glial cells express GR-immunoreactivity (-IR). 
In the prefrontal cortex and hippocampus, GCs are known to induce 
degeneration and cell death of neurons as well as proliferation of glial cells 
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(Haynes et al., 2001; Ramos-Remus et al., 2002; Tan et al., 2002). These 
findings are probably associated with learning and memory impairment 
after chronic exposure to GCs. Because GR is distributed in sensory and 
motor-related area of the brain (Cintra et al., 1994), GC is also considered to 
influence sensory and motor systems. A previous study has demonstrated 
that GC can affect microglial response to peripheral nerve transection in the 
facial nucleus (Kiefer and Kreutzberg et al., 1991). However, little is known 
about GC-induced degeneration, cell death or glial reaction in the TG, and 
cranial sensory and motor nuclei without axotomy. 
In this study, expression of ATF3, caspase-3 and CGRP was 
examined in the TG and brainstem after administration of prednisolone, a 
synthetic glucocorticoid. Immunohistochemistry for Iba1, glial fibrillary 
acidic protein (GFAP) and p38 MAPK was also performed to know effect of 
prednisolone on microglia and astrocytes in cranial nuclei of the brainstem 
(Suchorukova et al., 2010; Ichikawa et al., 2011). 
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Materials and methods 
 
Tissue preparation 
A total of 10 male Wistar rats (180-220 g) were used in this study. 
The animals were kept on a 12 h light/12 h dark cycle. Prednisorone (5 g/h, 
n = 4; Shionogi Pharma. Chemicals Co., Ltd., Japan) or saline (n = 4) was 
subcutaneously administered by an osmotic minipump (model 2ML2; Alzet, 
USA) for 7 days. Then, these animals were deeply anesthetized by 
sevoflurane inhalation to the level at which respiration was markedly 
suppressed and perfused through the left ventricle with saline for 20–40s for 
exsanguination followed by 0.1 M sodium phosphate buffer containing 4% 
formaldehyde (prepared fresh from paraformaldehyde, pH 7.4). The TG 
and brainstem were dissected and further fixed in a fresh volume of the 
fixative overnight at 4℃. The materials were cryoprotected by immersing 
until sunken in 0.02 M phosphate-buffered saline containing 20% sucrose 
(pH 7.4). The TG and brainstem were horizontally and frontally, 
respectively, frozen-sectioned at 8m. Two intact rats were also prepared 
as described above. 
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Immunohistochemistry 
For evaluation of neuronal degeneration and cell death, and glial 
reaction, ABC (avidin-biotin-horseradish peroxidase complex) and indirect 
immunofluorescence methods were performed. Sections of the TG and 
brainstem were incubated with rabbit polyclonal antiserum against ATF3 
(1:5000 for ABC, Santa Cruz Bio technology Inc., USA), cleaved caspase-3 
(1:3000 for ABC, Cell Signaling Technology, USA), CGRP (1:100000 for ABC, 
Peninsula Laboratory Inc. , USA), Iba1 (1:15000 for ABC, 1:250 for 
immunofluorescence, Wako Pure Chemical Industries Ltd. , Japan), GFAP 
(1:40000 for ABC, 1:1000 for immunofluorescence, Dako, Japan) or 
phosphorylated p38 (p-p38) MAPK (1:1000 for ABC, Cell Signaling, USA). 
For ABC method, sections were incubated with biotinylated goat anti-rabbit 
IgG (1:200, Vector Laboratories, USA) and ABC-complex (1:25, Vector 
Laboratories). Following nickel ammonium sulfate (0.1%)-intensified 
diaminobenzidine (0.002%) reaction, these sections were dehydrated in a 
graded series of alcohols, cleared in xylene and cover-slipped with Entellan 
(Merck). For immunofluorescence method, sections were incubated with 
lissamine rhodamine B chloride-conjugated donkey anti-rabbit IgG (1:300, 
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Jackson ImmunoResearch Labs., USA). The sections were viewed with 
light or fluorescence microscopy (Nikon, Japan). The specificity of rabbit 
antiserum against ATF3 or caspase-3 has been described elsewhere 
(Sugimoto et al., 1997, 2004). In addition, the normal rabbit serum was 
used instead of primary antibodies. No immunoreaction was detected in 
the control. 
 
Morphometric analysis 
For analysis of distribution and morphology of Iba1-IR cells in the 
cranial sensory and motor nuclei, 3 ABC-stained sections were randomly 
selected in each animal. The mesencephalic nucleus, nucleus principalis, 
and subnuclei oralis, interpolaris and caudalis of the trigeminal sensory 
complex as well as the trigeminal motor, facial and hypoglossal nuclei were 
identified under a dark field microscopy. Light and dark field microscopic 
images were stored into a personal computer, and superimposed by Lumina 
Vision program (Mitani Corporation, Japan). For density of Iba1-IR cells, 
the number of Iba1-IR cells was counted and its proportion to the area of the 
cranial nucleus (unit/mm2) was calculated for each section (LuminaVision 
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program). For morphological analysis of Iba1-IR cells, 5 and 10 Iba1-IR 
cells in hypoglossal and other cranial nuclei, respectively, were randomly 
selected from each section and the length of Iba1-IR processes was 
measured. The average of density of Iba1-IR cells and length of their 
processes was recorded for each animal. All the difference between saline- 
and prednisolone-treated animals was analyzed by Student’s t-test.  
The experiments were carried out under the control of the Animal 
Research Control Committee in accordance with The Guidelines for Animal 
Experiments of Tohoku University, Government Animal Protection and 
Management Law (No. 105), and Japanese Government Notification on 
Feeding and Safekeeping of Animals (No. 6). All efforts were made to 
minimize the number of animals used and their suffering. 
 
Results 
 
ATF3, CGRP and caspase-3 in the TG and brainstem 
In intact and saline-treated animals, the TG contained few ATF3-IR 
neurons (Fig. 4A). The IR was restricted to the nucleus within sensory 
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neurons. ATF3-IR neurons were also rare in the TG after prednisolone 
treatment (Fig. 4B). Less than 1 % of TG neurons showed ATF3-IR in 
saline- or prednisolone-treated animals. The cranial sensory and motor 
nuclei were devoid of ATF3-IR profiles in intact, and saline- or 
prednisolone-treated animals. In intact animals, many CGRP-IR motor 
neurons were observed in the trigeminal motor, facial and hypoglossal nuclei. 
CGRP-IR nerve fibers were also abundant in the subnuclei caudalis and 
oralis of the trigeminal sensory complex. The distribution of CGRP-IR in 
the brainstem appeared to be unchanged by saline or prednisolone treatment 
(Fig. 4C, D). The TG and brainstem were devoid of caspase-3-IR profiles in 
all examined animals. 
 
Iba1, GFAP and p-p38 MAPK in the brainstem 
In intact and saline-treated animals, Iba1- and GFAP-IR were 
detected in numerous cells in the cranial sensory and motor nuclei (Fig. 
4E-H, M, N). These cells were distributed throughout the trigeminal sensory 
and motor, facial and hypoglossal nuclei. They had small cell bodies and 
some processes (Fig. 4E-H, M, N). The number of Iba1-IR cells in the 
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brainstem was barely affected by prednisolone treatment. As a result, 
density of Iba1-IR cells was similar in cranial sensory and motor nuclei of 
saline- and prednisolone-treated animals (Fig. 5). However, prednisolone 
treatment had an effect on morphology of Iba1-IR cells in the subnucleus 
caudalis of the trigeminal sensory complex. In superficial and deep layers of 
the subnucleus, their processes extended many branches with repeated 
ramification (Fig. 4E-L). Compared to saline-treated animals, the length of 
Iba1-IR processes significantly increased in the subnucleus caudalis of 
prednisolone-treated animals (Fig. 6). The morphology of Iba1-IR cells was 
similar in other portions of the brainstem of intact, and saline- or 
prednisolone-treated animals. Prednisolone treatment scarcely influenced 
distribution or morphology of GFAP-IR cells in the brainstem (Fig. 4M-P). 
The expression of p-p38 MAPK-IR was very rare in the brainstem of 
salineand prednisolone-treated animals (figure not shown). 
 
Discussion 
The present study demonstrated that ATF-3 and caspase-3 were 
absent or very infrequent in the TG and brainstem of intact, and saline- or 
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prednisolone-treated animals. In addition, distribution of CGRP-IR was 
similar in the cranial motor nuclei of these animals. Therefore, we could not 
obtain the data that prednisolone induced neuronal degeneration or cell 
death in the TG or brainstem. Prednisone and dexamethasone are known to 
cause neuronal degeneration in the prefrontal cortex and hippocampus 
(Ramos-Remus et al., 2002; Tan et al., 2002). Dexamethasone induces 
neuronal cell death in the hippocampus of adult animals (Haynes et al., 
2001). In the neonatal hippocampus, neuronal apoptosis is increased by 
methylprednisolone (Schubert et al., 2005). However, the prefrontal cortex 
and hippocampus are devoid of caspase-3-IR in saline- or 
prednisolone-treated animals (our own unpublished data). It is unlikely that 
prednisolone causes severe damages to neurons in the cortex, hippocampus 
and brainstem. The variety of degenerative and apoptotic effects of GCs on 
brain neurons may depend on their molecular structures.  
Iba1 and GFAP were expressed by small cells in the brainstem of 
intact animals. The density of Iba1- and GFAP-IR cells was similar in the 
cranial sensory and motor nuclei of animals with and without prednisolone 
treatment. Iba1 and GFAP are considered to be markers for microglia and 
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astrocytes, respectively (Suchorukova et al., 2010; Ichikawa et al., 2011). 
Thus, it is suggested that prednisolone has little or no effect on the number 
of microglia and astrocytes in the cranial nuclei. The morphology of these 
glial cells was also similar in the cranial motor nuclei of saline- and 
prednisolone-treated animals. In the trigeminal sensory complex, however, 
prednisolone treatment increased the length of processes of Iba1-IR cells. 
Prednisolone probably increases ramification of microglial processes in the 
cranial sensory nucleus. The GC may be unable to activate p38 MAPK in 
glial cells, because expression of p-p38 MAPK was infrequent in saline- and 
prednisolone-treated brainstems. 
Capsaicin can activate the transient receptor potential, subfamily V, 
member 1 (TRPV1) receptor in primary nociceptors with small cell bodies  
(Caterina et al., 1997; Ichikawa and Sugimoto, 2001). A previous study has 
demonstrated that injection of capsaicin into the whisker pad activates 
microglia in the subnucleus caudalis of the trigeminal sensory complex 
(Kuroi et al., 2012). The treatment causes increase of ramified microglia and 
decrease of ameboid microglia. These findings are similar to the present 
observations that prednisolone increased ramification of microglial processes 
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in the subnucleus caudalis. In the TG, primary nociceptors such as TRPV1- 
and CGRP-containing neurons project to the subnucleus caudalis (Sugimoto 
et al., 1997, Bae et al., 2004). In the subnucleus, microglial activation is 
associated with development of oro-facial pain after nerve injury and 
inflammation (Lee et al., 2010). Therefore, microglial activation in the 
subnucleus caudalis by prednisolone treatment may suggest that the GC 
affects primary nociceptors in the TG and nociceptive transmission in the 
subnucleus. This suggestion may be supported by the previous finding that 
CGRP-IR nociceptors in the TG also showed GR-IR (DeLeón et al., 1994). On 
the other hand, prednisolone is known to cross the blood brain barrier 
(Bannwarth et al., 1997). Thus, the possibility that the GC directly acts on 
neurons and/or microglia within the subnucleus caudalis cannot be excluded. 
 In intact brains, microglial processes make contacts with neuronal 
synapses at an interval of one hour (Wake et al., 2009). The duration of the 
microglia-synapse contacts is markedly prolonged after cerebral ischemia. In 
this study, relationship between ramified processes of microglia and 
nociceptive neurons in the subnucleus caudalis after prednisolone treatment 
is unclear. Further studies will be necessary to know mechanism and 
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significance of prednisorone-induced microglial activation. 
 
Conclusion 
In the subnucleus caudalis of the trigeminal sensory complex, 
prednisolone increased ramification of microglial processes. The 
glucocorticoid may affect nociceptive transmission in the brainstem. 
 
References 
Chapter 1 
Bannwarth B, Schaeverbeke T, Péhourcq F, Vernhes JP, D'Yvoire MB, Dehais 
J (1997) Prednisolone concentrations in cerebrospinal fluid after oral 
prednisone. Preliminary data.  Rev Rhum Engl Ed 64:301-304. 
Cintra A, Zoli M, Rosén L, Agnati LF, Okret S, Wikström AC, Gustaffsson JA, 
Fuxe K (1994) Mapping and computer assisted morphometry and 
microdensitometry of glucocorticoid receptor immunoreactive neurons and 
glial cells in the rat central nervous system.  Neuroscience 62: 843-897. 
Clark JH, Schrader WT, O’Malley BW(1992) Mechanism of action of steroid 
hormones. Text of Endocrinology. Saunders, Philadelphia, 8th 
24 
 
Edition:35-90  
Fardet L, Flahault A, Kettaneh A, Tiev KP, Generean T, Toledano C, Lebbe C, 
Cabane J(2007)Corticosteroid-induced clinical adverse events: frequency, 
risk factors and patients’s opinion.  Br J Dermatol 2007; 157:142-148 
Fuxe K, Härfstrand A, Agnati LF, Yu ZY, Cintra A, Wikström AC, Okret S, 
Cantoni E, Gustafsson JA (1985) Immunocytochemical studies on the 
localization of glucocorticoid receptor immunoreactive nerve cells in the 
lower brain stem and spinal cord of the male rat using a monoclonal 
antibody against rat liver glucocorticoid receptor.  Neurosci Lett. 60:1-6. 
Haynes LE, Griffiths MR, Hyde RE, Barber DJ, Mitchell IJ (2001) 
Dexamethasone induces limited apoptosis and extensive sublethal 
damage to specific subregions of the striatum and hippocampus: 
implications for mood disorders.  Neuroscience 104:57-69. 
Herold MJ, McPherson KG, Reichardt HM (2006) Glucocorticoids in T cell 
apoptosis and function.  Cell Mol Life Sci 63:60-72. 
Meldy JC (1974) Systemic corticosteroid therapy; pharmacological and 
endcrinologic considerations.  Ann Intern Med 81:505 
Ramos-Remus C, González-Castañeda RE, González-Perez O, Luquin S, 
25 
 
García-Estrada J (2002) Prednisone induces cognitive dysfunction, 
neuronal degeneration, and reactive gliosis in rats.  J Investig Med 
50:458-464. 
Tan CK, Yan J, Ananth C, Kaur C (2002) Dexamethasone induces dendritic 
alteration but not apoptosis in the neurons of the hippocampus in 
postnatal rats.  Neurosci Lett 326:206-210. 
Wang YJ, Sakamoto S, Shinoda H (2000) Effects of long-term administration 
of methylprednisolone on the formation of dentin and enamel in rats.  
Tohoku Univ Dent J 19:175-187. 
 
Chapter 2 
Bae YC, Oh JM, Hwang SJ, Shigenaga Y, Valtschanoff JG (2004) Expression 
of vanilloid receptor TRPV1 in the rat trigeminal sensory nuclei. J Comp 
Neurol 478:62-71. 
Bannwarth B, Schaeverbeke T, Péhourcq F, Vernhes JP, D'Yvoire MB, Dehais 
J (1997) Prednisolone concentrations in cerebrospinal fluid after oral 
prednisone. Preliminary data.  Rev Rhum Engl Ed 64:301-304. 
Caterina MJ, Schumacher MA, Tominaga, Rosen TA, Levine JD, Julius D 
26 
 
(1997) The capsaicin receptor: a heat-activated ion channel in the pain 
pathway. Nature 389: 816-824. 
Cintra A, Zoli M, Rosén L, Agnati LF, Okret S, Wikström AC, Gustaffsson JA, 
Fuxe K (1994) Mapping and computer assisted morphometry and 
microdensitometry of glucocorticoid receptor immunoreactive neurons and 
glial cells in the rat central nervous system.  Neuroscience 62: 843-897. 
DeLeón M, Coveñas R, Chadi G, Narváez JA, Fuxe K, Cintra A (1994) 
Subpopulations of primary sensory neurons show coexistence of 
neuropeptides and glucocorticoid receptors in the rat spinal and 
trigeminal ganglia.  Brain Res 636:338-342. 
Fukuoka T, Tokunaga A, Kondo E, Miki K, Tachibana T, Noguchi K (1999) 
Differential regulation of alpha- and beta-CGRP mRNAs within 
oculomotor, trochlear, abducens, and trigeminal motoneurons in response 
to axotomy. Brain Res Mol Brain Res 63:304-315. 
Fuxe K, Härfstrand A, Agnati LF, Yu ZY, Cintra A, Wikström AC, Okret S, 
Cantoni E, Gustafsson JA (1985) Immunocytochemical studies on the 
localization of glucocorticoid receptor immunoreactive nerve cells in the 
lower brain stem and spinal cord of the male rat using a monoclonal 
27 
 
antibody against rat liver glucocorticoid receptor.  Neurosci Lett. 60:1-6. 
Grothe C (1993) Biphasic increase of calcitonin gene-related peptide-like 
immunoreactivity in rat hypoglossal motoneurons after nerve transection.  
Acta Histochem 94:20-24. 
Haynes LE, Griffiths MR, Hyde RE, Barber DJ, Mitchell IJ (2001) 
Dexamethasone induces limited apoptosis and extensive sublethal 
damage to specific subregions of the striatum and hippocampus: 
implications for mood disorders.  Neuroscience 104:57-69. 
Herold MJ, McPherson KG, Reichardt HM (2006) Glucocorticoids in T cell 
apoptosis and function.  Cell Mol Life Sci 63:60-72. 
Ichikawa H, Sato T, Kano M, Suzuki T, Matsuo S, Kanetaka H, Shimizu Y 
(2011) Masseteric nerve injury increases expression of brain-derived 
neurotrophic factor in microglia within the rat mesencephalic trigeminal 
tract nucleus.  Cell Mol Neurobiol 31:551-559.  
Ichikawa H, Sugimoto T (2001) VR1-immunoreactive primary sensory 
neurons in the rat trigeminal ganglion. Brain Res 890:184-188. 
Kiefer R, Kreutzberg GW (1991) Effects of dexamethasone on microglial 
activation in vivo: selective downregulation of major histocompatibility 
28 
 
complex class II expression in regenerating facial nucleus.  J 
Neuroimmunol 34:99-108. 
Kuroi T, Shimizu T, Shibata M, Toriumi H, Funakubo M, Iwashita T, SatoH, 
Koizumi K, Suzuki N (2012) Alterations in microglia and astrocytes in the 
trigeminal nucleus caudalis by repetitive TRPV1 stimulation on the 
trigeminal nociceptors. Neuroreport 23:560-565. 
Laskawi R, Wolff JR (1996) Changes in glial fibrillary acidic protein 
immunoreactivity in the rat facial nucleus following various types of nerve 
lesions.  Eur Arch Otorhinolaryngol 253:475-480. 
Lee S, Zhao YQ, Ribeiro-da-Silva A, Zhang J (2010) Distinctive response of 
CNS glial cells in oro-facial pain associated with injury, infection and 
inflammation.  Mol Pain 6:79. 
Park BG, Lee JS, Lee JY, Song DY, Jeong SW, Cho BP (2011) Co-localization 
of activating transcription factor 3 and phosphorylated c-Jun in 
axotomized facial motoneurons.  Anat Cell Biol 44:226-237. 
Ramos-Remus C, González-Castañeda RE, González-Perez O, Luquin S, 
García-Estrada J (2002) Prednisone induces cognitive dysfunction, 
neuronal degeneration, and reactive gliosis in rats.  J Investig Med 
29 
 
50:458-464. 
Schubert S, Stoltenburg-Didinger G, Wehsack A, Troitzsch D, Boettcher W, 
Huebler M, Redlin M, Kanaan M, Meissler M, Lange PE, Abdul-Khaliq H 
(2005) Large-dose pretreatment with methylprednisolone fails to 
attenuate neuronal injury after deep hypothermic circulatory arrest in a 
neonatal piglet model. Anesth Analg 101:1311-1318. 
Suchorukova EG, Kirik OV, Korzhevskii DE (2010) The use of 
immunohistochemical method for detection of brain microglia in paraffin 
sections.  Bull Exp Biol Med 149:768-770. 
Streit WJ, Dumoulin FL, Raivich G, Kreutzberg GW (1989) Calcitonin 
gene-related peptide increases in rat facial motoneurons after peripheral 
nerve transection.  Neurosci Lett 101:143-148. 
Sugimoto T, Fujiyoshi Y, Xiao C, He YF, Ichikawa H (1997) Central projection 
of calcitonin gene-related peptide (CGRP)- and substance P 
(SP)-immunoreactive trigeminal primary neurons in the rat.  J Comp 
Neurol 378:425-442. 
Sugimoto T, Jin H, Fijita M, Fukunaga T, Nagaoka N, Yamaai T, Ichikawa H 
(2004) Induction of activated caspase-3-immunoreactivity and apoptosis in 
30 
 
the trigeminal ganglion neurons by neonatal peripheral nerve injury.  
Brain Res 1017:238-243. 
Tan CK, Yan J, Ananth C, Kaur C (2002) Dexamethasone induces dendritic 
alteration but not apoptosis in the neurons of the hippocampus in 
postnatal rats.  Neurosci Lett 326:206-210. 
Terayama R, Fujisawa N, Yamaguchi D, Omura S, Ichikawa H, Sugimoto T 
(2011) Differential activation of mitogen-activated protein kinases and 
glial cells in the trigeminal sensory nuclear complex following lingual 
nerve injury. Neurosci Res 69:100-110. 
Tsuzuki K, Kondo E, Fukuoka T, Yi D, Tsujino H, Sakagami M, Noguchi K 
(2001) Differential regulation of P2X(3) mRNA expression by peripheral 
nerve injury in intact and injured neurons in the rat sensory ganglia.  
Pain 91:351-360. 
Vanderluit JL, McPhail LT, Fernandes KJ, McBride CB, Huguenot C, Roy S, 
Robertson GS, Nicholson DW, Tetzlaff W (2000) Caspase-3 is activated 
following axotomy of neonatal facial motoneurons and caspase-3 gene 
deletion delays axotomy-induced cell death in rodents.  Eur J Neurosci 
12:3469-3480. 
31 
 
Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J (2009) Resting 
microglia directly monitor the functional state of synapses in vivo and 
determine the fate of ischemic terminals. J Neurosci 29:3974-3980. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
Figure legends 
Fig.1 Relationship between the steroid therapy and SD-toothache  
The patients treated with steroid pulse therapy more frequently felt the 
SD-toothache than the patients without steroid pulse therapy. *p<0.05 
Fig.2  Relationship between dose of prednisolone and the VAS of 
SD-toothache 
Toothache magnitude was measured using a visual analogue scale (VAS). 
Fig.3 The features of SD-toothache  
The time point when SD-toothache appeared after onset of steroid therapy 
(A). The appearance within 3 months was the most frequent (mean: 94.8 
days). Types of trigger of SD-toothache (B). The most of patients 
(approximately 84%) felt SD-toothache by cold water and approximately 24% 
of patients felt pain even by hot water. The degree of SD-toothache (C). 
“Tolerable” was the most frequent (approximately 64%), but 31% of the 
patients complained of “intolerable” symptoms. The patients who answered 
“hardly anxious” were few.  
Fig.4 Microphotographs of the TG and brainstem of the rats 
Microphotographs for ATF3 (A, B), CGRP (C, D), Iba1 (E-L) and GFAP (M-P) 
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in the TG (A, B) and brainstem (E-P) after saline (A, C, E-H, M, N) and 
prednisolone (B, D, I-L, O, P) treatments.  ATF3-IR neurons (arrows in A, B) 
are very rare in saline (A)- and prednisolone (B)- treated TGs.  The 
distribution and morphology of CGRP-IR motoneurons are similar in the 
facial nucleus of saline (C)- and prednisolone (D)- treated animals.  Panels 
E, I, M and O were obtained under dark field microscopy.   Panels E and F, I 
and J, M and N, and O and P are the same fields of view, respectively.  In 
superficial (SL in E, F, I, J, and G, K) and deep layers (DL in E, F, I, J, and H, 
L) of the subnucleus caudalis of the trigeminal sensory complex, dendritic 
processes of Iba1-IR cell develop after treatment of prednisolone(I-L) but not 
saline (E-H).  Saline (M, N) or prednisolone (O, P) treatment has a little or 
no effect on GFAP-IR cells in superficial (SL in M, N) and deep layers (DL in 
M, N) of the subnucleus caudalis.  Bras = 200 m (A, E) and 50 m (G).  
Panels A-D, E, F, I and J, and G, H, K and L are at the same magnification, 
respectively. 
Fig. 5 The density of microglial cells  
Bar graphs showing mean density S.D. (unit/mm2) of Iba1-IR cells in the 
cranial sensory and motor nuclei after saline (open column) and prednisolone 
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(gray column) treatment.  The data were obtained from 4 saline-treated and 
4 prednisolone-treated animals. 
Fig. 6 The length of dendritic prosesses of the microglial cells  
Bar graphs showing mean length  S.D. (m) of dendritic processes of 
Iba1-IR cells in the cranial sensory and motor nuclei after saline (open 
column) and prednisolone (gray column) treatment.  The data were 
obtained from 4 saline-treated and 4 prednisolone-treated animals.  
Differences are statistically analyzed by Student’s t-test (*p < 0.01) 
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